Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance

21 Oct 2021

Abstract excerpt

Triple-negative breast cancer is a combative cancer type with a highly inflated histological grade that leads to poor theragnostic value. Gene, protein, and receptor-specific targets have shown effective clinical outcomes in patients with TNBC. Cells are frequently exposed to DNA-damaging agents. DNA damage is repaired by multiple pathways; accumulations of mutations occur due to damage to one or more pathways...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Plant Genetic and Mutation Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34829741
DOI: 10.3390/biomedicines9111512

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and ResistancePMID 34829741Read ↗

BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.Semantic proximity Read ↗

Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast CancerSemantic proximity Read ↗

PARP inhibitors in breast cancer: BRCA and beyond.Semantic proximity Read ↗

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.Semantic proximity Read ↗

PARP inhibitors in the management of breast cancer: current data and future prospects.Semantic proximity Read ↗

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancersSemantic proximity Read ↗

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor ResistanceSemantic proximity Read ↗

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read ↗

Therapeutic advances and application of PARP inhibitors in breast cancerSemantic proximity Read ↗

PARP Inhibitors in Breast and Ovarian CancerSemantic proximity Read ↗

PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.Semantic proximity Read ↗

PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.